NERV Stock Is on the Move, but Is It a Buy? Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings… Previous Article How to Quickly Adapt to Change and Future-Proof Your Business Next Article Looking to Hire a Marketer? Here's Why You Should Think Twice.
